Public source

Reviewed 9 Jun 2026

Completeness Fair (39%)

Aiforia® Gastric Cancer

Aiforia Technologies Plc

Aiforia® Gastric Cancer is an AI solution assisting pathologists in identifying carcinoma areas in digitized H&E-stained gastric tissue samples. It supports diagnostic decision-making while ensuring pathologists maintain full control to review or modify AI findings before final report approval.

No papers to support — we monitor for new evidence.

General Information

Product name

Aiforia® Gastric Cancer

Modality

Histopathology

Main task

Detection, Segmentation

Subspeciality

Gastrointestinal pathology

Organ/Specimen source

Not specified

Disease targeted

Gastric cancer

Specimen type

Not specified

Staining

H&E

Stain subtype

Not specified

Regulatory Information

CE-IVD Certification

Pathway:

In Vitro Diagnostic Regulation (IVDR)

Class:

Class C

Not verified by Health AI Register

Scanner Brands Certified for Use (CE-IVD)

Not specified

Scanner Models Certified for Use (CE-IVD)

Not specified

Other certifications

Not specified

Evidence & Research

No research papers or evidence on file yet.

The registry monitors publications for new evidence.

Technical Specifications

Patient population age

Not specified

Input

Digitized H&E-stained gastric tissue samples.

Input format

Not specified

Output

Detected tumour areas are visualized on the digital slide, and AI results are populated on the case-level report.

Output format

Not specified

Integration

Not specified

Deployment

Cloud-based, Hybrid

Trigger for analysis

Not specified

Processing time

Not specified

Population

Not specified

Viewer systems

Aiforia Clinical Suite Viewer

Market Presence

On market since

February 2026

AI Platforms

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Not specified

Based on

Not specified

Source: Public | First published: Apr 11, 2026 | Last updated: Jun 9, 2026

Aiforia® Gastric Cancer - Aiforia Technologies Plc